

# Jun S Wei

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4699447/publications.pdf>

Version: 2024-02-01

53  
papers

7,413  
citations

186265

28  
h-index

182427

51  
g-index

57  
all docs

57  
docs citations

57  
times ranked

10559  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dentithecamides Aâ€“H, Diacylated Zoanthoxanthin Derivatives with PAX3-FOXO1 Inhibitory Activity from the Hydroid <i>Dentitheca habererii</i> . <i>Journal of Natural Products</i> , 2022, 85, 1419-1427.	3.0	1
2	Pathogenic Germline Variants in Cancer Susceptibility Genes in Children and Young Adults With Rhabdomyosarcoma. <i>JCO Precision Oncology</i> , 2021, 5, 75-87.	3.0	27
3	Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repairâ€“targeted therapies. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	35
4	Aneurysmal Fibrous Histiocytoma: A Large Soft Tissue Tumor with Metastases Treated with Palliative Radiation Therapy and Targeted Therapy. <i>Case Reports in Oncology</i> , 2021, 14, 17-23.	0.7	1
5	Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. <i>Cancer Cell</i> , 2021, 39, 566-579.e7.	16.8	107
6	Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer. <i>Nature Communications</i> , 2021, 12, 3880.	12.8	71
7	Ataxia telangiectasia mutated germline pathogenic variant in adrenocortical carcinoma. <i>Cancer Genetics</i> , 2021, 256-257, 21-25.	0.4	4
8	Report of Canonical <i>BCR</i> - <i>ABL1</i> Fusion in Glioblastoma. <i>JCO Precision Oncology</i> , 2021, 5, 1348-1353.	3.0	3
9	Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 2859-2871.	1.6	101
10	Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in <i>BAP1</i> Gene. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100231.	1.1	16
11	Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion. <i>Cancer Research</i> , 2021, 81, 5818-5832.	0.9	10
12	BAF complexes drive proliferation and block myogenic differentiation in fusion-positive rhabdomyosarcoma. <i>Nature Communications</i> , 2021, 12, 6924.	12.8	25
13	Immuno-transcriptomic profiling of extracranial pediatric solid malignancies. <i>Cell Reports</i> , 2021, 37, 110047.	6.4	26
14	Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas. <i>Cancers</i> , 2021, 13, 6092.	3.7	14
15	Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults With Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2020, 15, 457-461.	1.1	24
16	Dynamics of genomic and immune responses during primary immunotherapy resistance in mismatch repairâ€“deficient tumors. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a005678.	1.2	3
17	Somatic structural variation targets neurodevelopmental genes and identifies <i>SHANK2</i> as a tumor suppressor in neuroblastoma. <i>Genome Research</i> , 2020, 30, 1228-1242.	5.5	20
18	Miswired Enhancer Logic Drives a Cancer of the Muscle Lineage. <i>IScience</i> , 2020, 23, 101103.	4.1	26

#	ARTICLE	IF	CITATIONS
19	Clinical and Genomic Characteristics of Small Cell Lung Cancer in Never Smokers. <i>Chest</i> , 2020, 158, 1723-1733.	0.8	16
20	Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2. <i>Clinical Cancer Research</i> , 2020, 26, 3296-3306.	7.0	12
21	CASZ1 induces skeletal muscle and rhabdomyosarcoma differentiation through a feed-forward loop with MYOD and MYOG. <i>Nature Communications</i> , 2020, 11, 911.	12.8	32
22	Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer. <i>Cell Reports Medicine</i> , 2020, 1, 100007.	6.5	78
23	Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 601452.	2.8	1
24	Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9008-9013.	7.1	108
25	Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas. <i>Neuro-Oncology</i> , 2019, 21, 981-992.	1.2	69
26	Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer. <i>Hepatology</i> , 2019, 69, 2048-2060.	7.3	77
27	Detailed Multi-Method Analysis of Bone Marrow from Pediatric Pre-B-ALL Patients Prior to CD19-CAR-T Therapy Subsequently Evidencing Overt CAR-T Resistance. <i>Blood</i> , 2019, 134, 2744-2744.	1.4	3
28	Clonal evolution and osimertinib resistance mechanisms identified by whole exome and transcriptome sequencing in EGFR mutant NSCLC. <i>Journal of Clinical Oncology</i> , 2019, 37, 9049-9049.	1.6	0
29	Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma. <i>Cancer Discovery</i> , 2018, 8, 582-599.	9.4	119
30	Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN-Not-Amplified Human Neuroblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 5673-5684.	7.0	92
31	MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	104
32	Frequent inactivating germline mutations in DNA repair genes in patients with Ewing sarcoma. <i>Genetics in Medicine</i> , 2017, 19, 955-958.	2.4	60
33	PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability. <i>Cancer Discovery</i> , 2017, 7, 884-899.	9.4	221
34	Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. <i>Cancer Cell</i> , 2017, 32, 295-309.e12.	16.8	148
35	Paired Expression Analysis of Tumor Cell Surface Antigens. <i>Frontiers in Oncology</i> , 2017, 7, 173.	2.8	16
36	MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research. <i>Clinical Cancer Research</i> , 2016, 22, 3810-3820.	7.0	99

#	ARTICLE	IF	CITATIONS
37	MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma. <i>Cancer Letters</i> , 2016, 371, 214-224.	7.2	46
38	Identification of microRNAs specific for epithelial cell adhesion molecule <sup>+</sup> positive tumor cells in hepatocellular carcinoma. <i>Hepatology</i> , 2015, 62, 829-840.	7.3	51
39	Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. <i>Nature Genetics</i> , 2015, 47, 864-871.	21.4	451
40	Clonality and Evolutionary History of Rhabdomyosarcoma. <i>PLoS Genetics</i> , 2015, 11, e1005075.	3.5	58
41	Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism. <i>Nature</i> , 2015, 528, 418-421.	27.8	263
42	Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma. <i>Oncotarget</i> , 2015, 6, 35247-35262.	1.8	52
43	The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation. <i>PLoS Genetics</i> , 2014, 10, e1004475.	3.5	335
44	Expression Quantitative Trait Loci and Receptor Pharmacology Implicate Arg1 and the GABA-A Receptor as Therapeutic Targets in Neuroblastoma. <i>Cell Reports</i> , 2014, 9, 1034-1046.	6.4	28
45	Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors. <i>Cancer Discovery</i> , 2014, 4, 216-231.	9.4	596
46	The genetic landscape of high-risk neuroblastoma. <i>Nature Genetics</i> , 2013, 45, 279-284.	21.4	990
47	Massively Parallel Sequencing Reveals an Accumulation of De Novo Mutations and an Activating Mutation of LPAR1 in a Patient with Metastatic Neuroblastoma. <i>PLoS ONE</i> , 2013, 8, e77731.	2.5	24
48	EZH2 Mediates Epigenetic Silencing of Neuroblastoma Suppressor Genes <i>CASZ1</i> , <i>CLU</i> , <i>RUNX3</i> , and <i>NGFR</i> . <i>Cancer Research</i> , 2012, 72, 315-324.	0.9	161
49	Initial Genomic Analysis of a Pure Erythroid Leukemia Developing in Association with Hydroxyurea Treatment for Sickle Cell Anemia. <i>Blood</i> , 2012, 120, 3254-3254.	1.4	0
50	microRNA Profiling Identifies Cancer-Specific and Prognostic Signatures in Pediatric Malignancies. <i>Clinical Cancer Research</i> , 2009, 15, 5560-5568.	7.0	49
51	New technologies for diagnosing pediatric tumors. <i>Expert Opinion on Medical Diagnostics</i> , 2008, 2, 1205-1219.	1.6	5
52	Prediction of Clinical Outcome Using Gene Expression Profiling and Artificial Neural Networks for Patients with Neuroblastoma. <i>Cancer Research</i> , 2004, 64, 6883-6891.	0.9	183
53	Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. <i>Nature Medicine</i> , 2001, 7, 673-679.	30.7	2,352